Evidence map›Paper›PMID 31194692›Full record

ArticleRadiology and oncology2019

The use of high-frequency short bipolar pulses in cisplatin electrochemotherapy in vitro.

Maria Scuderi, Matej Rebersek, Damijan Miklavcic, Janja Dermol-Cerne

Open access · goldAbstract read
In one paragraph

Article in Radiology and oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Maria ScuderiUniversity of Padua, Department of Information Engineering, Padua, Italy.
Matej RebersekUniversity of Ljubljana, Faculty of Electrical Engineering, Ljubljana, Slovenia.
Damijan MiklavcicUniversity of Ljubljana, Faculty of Electrical Engineering, Ljubljana, Slovenia.
Janja Dermol-CerneUniversity of Ljubljana, Faculty of Electrical Engineering, Ljubljana, Slovenia.
University of Ljubljana · SIUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background In electrochemotherapy (ECT), chemotherapeutics are first administered, followed by short 100 μs monopolar pulses. However, these pulses cause pain and muscle contractions. It is thus necessary to administer muscle relaxants, general anesthesia and synchronize pulses with the heart rhythm of the patient, which makes the treatment more complex. It was suggested in ablation with irreversible electroporation, that bursts of short high-frequency bipolar pulses could alleviate these problems. Therefore, we designed our study to verify if it is possible to use high-frequency bipolar pulses (HF-EP pulses) in electrochemotherapy. Materials and methods We performed in vitro experiments on mouse skin melanoma (B16-F1) cells by adding 1-330 μM cisplatin and delivering either (a) eight 100 μs long monopolar pulses, 0.4-1.2 kV/cm, 1 Hz (ECT pulses) or (b) eight bursts at 1 Hz, consisting of 50 bipolar pulses. One bipolar pulse consisted of a series of 1 μs long positive and 1 μs long negative pulse (0.5-5 kV/cm) with a 1 μs delay in-between. Results With both types of pulses, the combination of electric pulses and cisplatin was more efficient in killing cells than cisplatin or electric pulses only. However, we needed to apply a higher electric field in HF-EP (3 kV/cm) than in ECT (1.2 kV/cm) to obtain comparable cytotoxicity. Conclusions It is possible to use HF-EP in electrochemotherapy; however, at the expense of applying higher electric fields than in classical ECT. The results obtained, nevertheless, offer an evidence that HF-EP could be used in electrochemotherapy with potentially alleviated muscle contractions and pain.

Indexed as

Muscle ContractionAnimalsAntineoplastic AgentsCell Line, TumorCell Membrane PermeabilityCell SurvivalCisplatinElectrochemotherapyElectroporationIndicators and ReagentsIn Vitro TechniquesMelanoma, ExperimentalMiceProcedural PainPropidiumTime FactorsAntineoplastic AgentsCisplatinIndicators and ReagentsPropidiumcell survivalcisplatindrug uptakeelectrochemotherapyelectroporationhigh-frequency bipolar pulses

Identifiers

PMID31194692
PMCPMC6572501
OpenAlexW2952508493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.